PPT-Switch to ATV- or ATV/r-containing regimen

Switch to ATVr containing regimen ATAZIP Switch to ATV rcontaining regimen SWAN Study SLOAT Study Switch to ATV containing regimen ARIES Study INDUMA Study ASSURE . r. + RAL. HARNESS Study. ATV/. r. 300/100 mg . qd. + TDF/FTC. N = 37. N = 72. ATV/r 300/100 mg . qd. + RAL 400 mg bid. Design. Randomisation. 2 : 1. Open-label. Objective. Primary Endpoint: proportion with treatment success at W24 . IE 500 Final Project – Fall 2014. Lathe Maintenance Ontology (LMO). Scope. Create an ontology which outlines a machines necessary preventative maintenance based on a set time period.. www.eptam.com. What Next?. CTCA Conference 2012. John Jereb, FSEB, DTBE, CDC. Special thanks to Christine Ho,. Elsa Villarino, and Andrey Borisov. The findings and conclusions in this presentation are those of the presenter and do not necessarily represent the views of CDC. S. tandardized . T. reatment . Re. gimen. . of . A. nti-Tuberculosis Drugs for Patients with . M. DR-TB (. ST. REAM. ). Nehemiah Nhando. UZ-UCSF ANNUAL RESEARCH DAY . 08 April 2016. Harare. 2. 3. DR-TB case detection in . SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A4001078. VEMAN. . MODERN. A4001078 . Study. : ATV/r + MVC vs ATV/r + TDF/FTC . Design. ≥ 16 . years. HIV+. Antiretroviral. . naive. HIV-1 RNA ≥ 1 000 c/. Study GS-US-292-0119. E/C/F/TAF + DRV 800 mg QD. N = 89. N = 46. Baseline regimen. Design. Randomisation*. 2: 1. Open-label. Objective. Primary Endpoint: proportion with treatment success (HIV RNA < 50 c/mL) . in . Bangkok . MSM . (HPTN . 067/ADAPT Study). Tareerat . Chemnasiri, . Anchalee . Varangrat, . K. Rivet . Amico. , . Supaporn. . Chaikummao. , . Anupong. . Chitwarakorn. , . Bonnie J. . Dye, . Robert M. . ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . GS-US-216-0114. . Gallant JE. JID 2013;208:32-9. GS-US-216-0114. Design. Objective. Non inferiority of COBI compared with RTV at W48: % HIV RNA < 50 c/mL . by intention to treat, snapshot analysis (lower limit for the 95% CI for the difference = -12%, 95% power). NDA 206353 ATV/COBI FDC CDTL Review mentioned phase III trialand a phase IItrialTrialGS-US-216-0105 as reviewed in NDA The findings of this study was extrapolatedto HIV-1treatment-experienced patients Volume 6 , No. 4 128 QiaoSheng DONG University of Cambridge , U K E mail : dongqiaosheng@gmail.com Abstract : When considering the cause of diseases, the Hippocratic authors paid much attention to th Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . ACTG 5202. EFV versus ATV/r, both with ABC-3TC or TDF-FTC. ACTG 5202: Study Design. Source: . Daar. ES, et al. . Ann Intern Med. 2011;154:445-56. . EFV + ABC-3TC. (n = 465). ATV + RTV + ABC-3TC. (n = 463). DRIVE SHIFT. Switch to Doravirine-TDF-3TC versus Continued Baseline Regimen. DRIVE SHIFT: Design. Source: Johnson M, et al. J . Acquir. . Immun. . Defic. . Syndr. . 2019;81:463-72.. Design: . Open-label, non-inferiority trial in adults with suppressed HIV RNA while taking 2 NRTIs plus anchor drug, randomized (2:1) to immediately switch to fixed-dose .